The effect of anakinra in hospitalized patients with covid-19: An updated systematic review and meta-analysis

17Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

The role of immunomodulatory agents in the treatment of hospitalized patients with COVID-19 has been of increasing interest. Anakinra, an interleukin-1 inhibitor, has been shown to offer significant clinical benefits in patients with COVID-19 and hyperinflammation. An updated systematic review and meta-analysis regarding the impact of anakinra on the outcomes of hospitalized patients with COVID-19 was conducted. Studies, randomized or non-randomized with adjustment for confounders, reporting on the adjusted risk of death in patients treated with anakinra versus those not treated with anakinra were deemed eligible. A search was performed in PubMed/EMBASE databases, as well as in relevant websites, until 1 August 2021. The meta-analysis of six studies that fulfilled the inclusion criteria (n = 1553 patients with moderate to severe pneumonia, weighted age 64 years, men 66%, treated with anakinra 50%, intubated 3%) showed a pooled hazard ratio for death in patients treated with anakinra at 0.47 (95% confidence intervals 0.34, 0.65). A meta-regression analysis did not reveal any significant associations between the mean age, percentage of males, mean baseline C-reactive protein levels, mean time of administration since symptoms onset among the included studies and the hazard ratios for death. All studies were considered as low risk of bias. The current evidence, although derived mainly from observational studies, supports a beneficial role of anakinra in the treatment of selected patients with COVID-19.

References Powered by Scopus

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

45898Citations
N/AReaders
Get full text

Bias in meta-analysis detected by a simple, graphical test

42603Citations
N/AReaders
Get full text

Operating characteristics of a rank correlation test for publication bias

13984Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

43Citations
N/AReaders
Get full text

Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy

19Citations
N/AReaders
Get full text

COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kyriakoulis, K. G., Kollias, A., Poulakou, G., Kyriakoulis, I. G., Trontzas, I. P., Charpidou, A., & Syrigos, K. (2021, October 1). The effect of anakinra in hospitalized patients with covid-19: An updated systematic review and meta-analysis. Journal of Clinical Medicine. MDPI. https://doi.org/10.3390/jcm10194462

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

85%

Researcher 2

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

60%

Biochemistry, Genetics and Molecular Bi... 4

27%

Pharmacology, Toxicology and Pharmaceut... 1

7%

Nursing and Health Professions 1

7%

Save time finding and organizing research with Mendeley

Sign up for free